<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00778336</url>
  </required_header>
  <id_info>
    <org_study_id>PEARL</org_study_id>
    <nct_id>NCT00778336</nct_id>
  </id_info>
  <brief_title>A Prospective Observational Registry of Peripheral Use of AngioJet Rheolytic Thrombectomy With Mid-Length Catheters</brief_title>
  <official_title>Peripheral Use of AngioJet Rheolytic Thrombectomy With Mid-Length Catheters</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This registry collects observational data about how mid-length AngioJet catheters (ie
      XPEEDIOR and DVX models) are used in routine clinical practice.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The PEARL Registry collects real world data about mid-length AngioJet catheters to:

        -  Characterize usage patterns, treatment approaches, and targeted vessels

        -  Document treatment strategies, including specific techniques and concomitant therapies

        -  Collect outcome data during initial hospitalization and at a 3-month follow-up phone
           call or visit

        -  Evaluate the frequency of specific clinical events in relation to risk factors,
           diagnosis, and treatments provided

        -  Identify treatment strategies that may optimize procedural and clinical outcomes, to
           facilitate development of treatment guidelines

        -  Offer sites a valuable resource for tracking usage and performance of the AngioJet
           System at their institution

      Information collected by the PEARL Registry is intended for educational and clinical research
      purposes only.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline to Final Angiographic Results</measure>
    <time_frame>Index Procedure ( pre-endovascular treatment and post-endovascular treatment)</time_frame>
    <description>From the Index Procedure's Baseline (pre-endovascular treatment) and Final (post-endovascular treatment) angiograms,each vessel was assigned a value by the treating physician:
complete occlusion (&gt; 90% occlusion);
substantial occlusion (50-90% occlusion OR &lt;50% occlusion and &gt;3cm in length);
partial occlusion (&lt;50% occlusion AND &lt;3cm in length);
patent (Without visable thrombus or occlusion).
The levels of change (improvement) were calculated by subtracting the baseline assigned angiographic value from the final value.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rethrombosis</measure>
    <time_frame>3 Month Follow Up</time_frame>
    <description>The number of patients that had rethrombosed in the vessels treated during the index procedure (initial endovascular procedure).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of Treatments by Thrombotic Condition</measure>
    <time_frame>Index Procedure</time_frame>
    <description>The # of patients that were exposed to each treatment at least once in the given thrombotic condition.</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">452</enrollment>
  <condition>Peripheral Vascular Diseases</condition>
  <condition>Thrombosis</condition>
  <condition>Venous Thrombosis</condition>
  <arm_group>
    <arm_group_label>Limb Ischemia</arm_group_label>
    <description>Patients presenting with limb ischemia for treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Deep Vein Thrombosis</arm_group_label>
    <description>Patients presenting with deep vein thrombosis for treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hemodialysis Access</arm_group_label>
    <description>Patients presenting with thrombosed hemodialysis access for treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Other Thrombotic Conditions</arm_group_label>
    <description>Patients presenting with thrombosed conditions other than limb ischemia, deep vein thrombosis or thrombosed hemodialysis access for treatment.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patient with peripheral thrombosis treated with a AngioJet mid-length catheter that is
        indicated for thrombosis removal.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient has been treated with a mid-length AngioJet catheter(defined as 90-120 cm in
             length)

          -  Patient has provided appropriate authorization per institutional policy and procedure.

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lawrence R. Blitz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chilton Memorial Hospital, Pompton Plains, NJ</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Lookstein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mount Sinai School of Medicine, NYC, NY</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eugene Simoni, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samaritan Vascular Institute, Dayton, OH</affiliation>
  </overall_official>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 22, 2008</study_first_submitted>
  <study_first_submitted_qc>October 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 23, 2008</study_first_posted>
  <results_first_submitted>February 22, 2011</results_first_submitted>
  <results_first_submitted_qc>March 28, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 26, 2011</results_first_posted>
  <last_update_submitted>October 8, 2014</last_update_submitted>
  <last_update_submitted_qc>October 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Peripheral Thrombosis</keyword>
  <keyword>DVT</keyword>
  <keyword>Limb Ischemia</keyword>
  <keyword>AV Access</keyword>
  <keyword>AngioJet</keyword>
  <keyword>Thrombectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients presenting at a participating site who were clinically indicated for a peripheral interventional(venous or arterial) procedure with the mid-length (90cm or 120cm catheters) catheter were offered the opportunity to participate. Patients were recruited from January 2007 thru December 2009.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Limb Ischemia</title>
          <description>Patients with limb ischemia treated with a midlength AngioJet catheter.</description>
        </group>
        <group group_id="P2">
          <title>Deep Vein Thrombosis</title>
          <description>Patients with deep vein thrombosis treated with a midlength AngioJet catheter.</description>
        </group>
        <group group_id="P3">
          <title>Hemodialysis Access</title>
          <description>Patients with thrombosed hemodialysis access treated with a midlength AngioJet catheter.</description>
        </group>
        <group group_id="P4">
          <title>Other Thrombotic Conditions</title>
          <description>Patients with a thrombotic Condition other than limb ischemia, deep vein thrombosis or thrombosed hemodialysis access treated with a midlength AngioJet catheter.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Index Procedure-Discharge</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="198"/>
                <participants group_id="P2" count="170"/>
                <participants group_id="P3" count="72"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="192"/>
                <participants group_id="P2" count="167"/>
                <participants group_id="P3" count="70"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>3 Month Follow Up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="192"/>
                <participants group_id="P2" count="167"/>
                <participants group_id="P3" count="70"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="169"/>
                <participants group_id="P2" count="144"/>
                <participants group_id="P3" count="65"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Limb Ischemia</title>
          <description>Patients with limb ischemia treated with a midlength AngioJet catheter.</description>
        </group>
        <group group_id="B2">
          <title>Deep Vein Thrombosis</title>
          <description>Patients with deep vein thrombosis treated with a midlength AngioJet catheter.</description>
        </group>
        <group group_id="B3">
          <title>Hemodialysis Access</title>
          <description>Patients with thrombosed hemodialysis access treated with a midlength AngioJet catheter.</description>
        </group>
        <group group_id="B4">
          <title>Other Thrombotic Conditions</title>
          <description>Patients with a thrombotic Condition other than limb ischemia, deep vein thrombosis or thrombosed hemodialysis access treated with a midlength AngioJet catheter.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="198"/>
            <count group_id="B2" value="170"/>
            <count group_id="B3" value="72"/>
            <count group_id="B4" value="12"/>
            <count group_id="B5" value="452"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67" spread="14"/>
                    <measurement group_id="B2" value="52" spread="17"/>
                    <measurement group_id="B3" value="63" spread="13"/>
                    <measurement group_id="B4" value="63" spread="18"/>
                    <measurement group_id="B5" value="61" spread="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="110"/>
                    <measurement group_id="B2" value="106"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="260"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="198"/>
                    <measurement group_id="B2" value="170"/>
                    <measurement group_id="B3" value="72"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="452"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to Final Angiographic Results</title>
        <description>From the Index Procedure's Baseline (pre-endovascular treatment) and Final (post-endovascular treatment) angiograms,each vessel was assigned a value by the treating physician:
complete occlusion (&gt; 90% occlusion);
substantial occlusion (50-90% occlusion OR &lt;50% occlusion and &gt;3cm in length);
partial occlusion (&lt;50% occlusion AND &lt;3cm in length);
patent (Without visable thrombus or occlusion).
The levels of change (improvement) were calculated by subtracting the baseline assigned angiographic value from the final value.</description>
        <time_frame>Index Procedure ( pre-endovascular treatment and post-endovascular treatment)</time_frame>
        <population>Intention to Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Limb Ischemia</title>
            <description>Patients treated with a midlength Angiojet catheter for limb ischemia</description>
          </group>
          <group group_id="O2">
            <title>Deep Vein Thrombosis</title>
            <description>Patients treated with a midlength Angiojet catheter for deep vein thrombosis</description>
          </group>
          <group group_id="O3">
            <title>Hemodialysis Access</title>
            <description>Patients treated with a midlength Angiojet catheter for thrombosed hemodialysis access sites</description>
          </group>
          <group group_id="O4">
            <title>Other Thrombotic Conditions</title>
            <description>Patients treated with a midlength Angiojet catheter for thrombotic conditions other than limb ischemia, deep vein thrombosis or thrombosed hemodialysis access</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Final Angiographic Results</title>
          <description>From the Index Procedure's Baseline (pre-endovascular treatment) and Final (post-endovascular treatment) angiograms,each vessel was assigned a value by the treating physician:
complete occlusion (&gt; 90% occlusion);
substantial occlusion (50-90% occlusion OR &lt;50% occlusion and &gt;3cm in length);
partial occlusion (&lt;50% occlusion AND &lt;3cm in length);
patent (Without visable thrombus or occlusion).
The levels of change (improvement) were calculated by subtracting the baseline assigned angiographic value from the final value.</description>
          <population>Intention to Treat (ITT)</population>
          <units>Occlusion Index</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="198"/>
                <count group_id="O2" value="170"/>
                <count group_id="O3" value="72"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (pre-treatment) Angiograph Value</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.32" spread="0.04"/>
                    <measurement group_id="O2" value="1.37" spread="0.04"/>
                    <measurement group_id="O3" value="1.16" spread="0.05"/>
                    <measurement group_id="O4" value="1.89" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final (post-treatment) Angiograph Value</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.67" spread="0.05"/>
                    <measurement group_id="O2" value="3.67" spread="0.04"/>
                    <measurement group_id="O3" value="3.80" spread="0.07"/>
                    <measurement group_id="O4" value="3.54" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Levels of Change (baseline minus final values)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.36" spread="0.06"/>
                    <measurement group_id="O2" value="2.30" spread="0.05"/>
                    <measurement group_id="O3" value="2.63" spread="0.08"/>
                    <measurement group_id="O4" value="1.63" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Alternative hypothesis is change in occlusion &gt; 0.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Alternative hypothesis is change in occlusion &gt; 0.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Alternative hypothesis is change in occlusion &gt; 0.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Alternative hypothesis is change in occlusion &gt; 0.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rethrombosis</title>
        <description>The number of patients that had rethrombosed in the vessels treated during the index procedure (initial endovascular procedure).</description>
        <time_frame>3 Month Follow Up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Limb Ischemia</title>
            <description>Patients treated with a midlength Angiojet catheter for limb ischemia</description>
          </group>
          <group group_id="O2">
            <title>Deep Vein Thrombosis</title>
            <description>Patients treated with a midlength Angiojet catheter for deep vein thrombosis</description>
          </group>
          <group group_id="O3">
            <title>Hemodialysis Access</title>
            <description>Patients treated with a midlength Angiojet catheter for thrombosed hemodialysis access sites</description>
          </group>
          <group group_id="O4">
            <title>Other Thrombotic Conditions</title>
            <description>Patients treated with a midlength Angiojet catheter for thrombotic conditions other than limb ischemia, deep vein thrombosis or thrombosed hemodialysis access</description>
          </group>
        </group_list>
        <measure>
          <title>Rethrombosis</title>
          <description>The number of patients that had rethrombosed in the vessels treated during the index procedure (initial endovascular procedure).</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="198"/>
                <count group_id="O2" value="170"/>
                <count group_id="O3" value="72"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Description of Treatments by Thrombotic Condition</title>
        <description>The # of patients that were exposed to each treatment at least once in the given thrombotic condition.</description>
        <time_frame>Index Procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Limb Ischemia</title>
            <description>Patients treated with a midlength Angiojet catheter for limb ischemia</description>
          </group>
          <group group_id="O2">
            <title>Deep Vein Thrombosis</title>
            <description>Patients treated with a midlength Angiojet catheter for deep vein thrombosis</description>
          </group>
          <group group_id="O3">
            <title>Hemodialysis Access</title>
            <description>Patients treated with a midlength Angiojet catheter for thrombosed hemodialysis access sites</description>
          </group>
          <group group_id="O4">
            <title>Other Thrombotic Conditions</title>
            <description>Patients treated with a midlength Angiojet catheter for thrombotic conditions other than limb ischemia, deep vein thrombosis or thrombosed hemodialysis access</description>
          </group>
        </group_list>
        <measure>
          <title>Description of Treatments by Thrombotic Condition</title>
          <description>The # of patients that were exposed to each treatment at least once in the given thrombotic condition.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="198"/>
                <count group_id="O2" value="170"/>
                <count group_id="O3" value="72"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AngioJet Thrombectomy without Lytic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="78"/>
                    <measurement group_id="O3" value="68"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AngioJet Thrombectomy + Lytic Delivery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121"/>
                    <measurement group_id="O2" value="144"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Balloon Angioplasty</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144"/>
                    <measurement group_id="O2" value="120"/>
                    <measurement group_id="O3" value="59"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stent Placement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96"/>
                    <measurement group_id="O2" value="48"/>
                    <measurement group_id="O3" value="30"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Atherectomy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Filter Placement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Catheter Directed Thrombolysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="79"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non AngioJet Thrombectomy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Index procedure thru Discharge, 3 Month Follow Up</time_frame>
      <desc>Events that were related to initial index procedure and/or AngioJet.</desc>
      <group_list>
        <group group_id="E1">
          <title>Limb Ischemia</title>
          <description>Patients with limb ischemia treated with a midlength AngioJet catheter.</description>
        </group>
        <group group_id="E2">
          <title>Deep Vein Thrombosis</title>
          <description>Patients with deep vein thrombosis treated with a midlength AngioJet catheter.</description>
        </group>
        <group group_id="E3">
          <title>Hemodialysis Access</title>
          <description>Patients with thrombosed hemodialysis access treated with a midlength AngioJet catheter.</description>
        </group>
        <group group_id="E4">
          <title>Other Thrombotic Conditions</title>
          <description>Patients with a thrombotic Condition other than limb ischemia, deep vein thrombosis or thrombosed hemodialysis access treated with a midlength AngioJet catheter.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="170"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemolytic Anemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="198"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Elevated Creatinine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Bleeding Requiring transfusion</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="198"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Non randomized observational registry</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>DeeAnn Tinjum</name_or_title>
      <organization>Boston Scientific Corporation</organization>
      <phone>763-450-8707</phone>
      <email>deeann.tinjum@bsci.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

